Post-ASH 2025 CLL Highlights

Featuring presentations & discussions on selected CLL abstracts from the 67^th ASH Annual Meeting and Exposition

Tuesday 10 February | 08:00 – 10:00 CST/ 14:00 – 16:00 GMT/ 15:00 – 17:00 CET

Chair: Kerry Rogers | Moderators: Deborah Stephens & Moritz Fürstenau

Register Now

Preliminary Agenda:

Welcome and introductions 

Session 1: Novel treatment approaches in CLL

Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial (ABSTRACT ID abs25-2071; ABSTRACT ID 1) | Speaker: Othman Al-Sawaf

MRD-guided ibrutinib plus venetoclax improves outcomes in CLL patients with TP53, ATM, or NOTCH1 aberrations compared to ibrutinib and FCR: Results from the Phase III NCRI FLAIR trial (ABSTRACT ID abs25-13782; ABSTRACT ID 679) | Speaker: TBC

Efficacy of 2nd-line treatment in CLL after venetoclax-based 1st-line treatment: Results from the GAIA/CLL13 trial (ABSTRACT ID abs25-7495; ABSTRACT ID 795) | Speaker: Carsten Niemann

Panel Discussion

Session 2: Novel BTKi monotherapy approaches for CLL  

Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor (ABSTRACT ID abs25-2587; ABSTRACT ID 683) | Speaker: Jennifer Woyach

Pirtobrutinib outcomes in second-line (2L) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after first-line (1L) cBTKi therapy: A pooled analysis from the BRUIN LOXO-BTK-18001 and BRUIN CLL-321 studies (ABSTRACT ID abs25-7227; ABSTRACT ID 5670) | Speaker: Toby Eyre

Updates of R/R CLL with prior exposure to Bruton’s tyrosine kinase (BTK) inhibitor and/or bcl-2 inhibitor in the Phase 1 trial of LP-168 (Rocbrutinib), a novel COVALENT and non-COVALENT BTK inhibitor (ABSTRACT ID abs25-2620; ABSTRACT ID 87) | Speaker: Jennifer Woyach

Panel Discussion

Session 3: Novel BTKi combination approaches for CLL

A post hoc safety analysis of fixed-duration acalabrutinib-venetoclax combinations vs chemoimmunotherapy: Results from the phase 3 AMPLIFY trial (ABSTRACT ID abs25-8154; ABSTRACT ID 2118) | Speaker: Jennifer Brown

Nemtabrutinib plus venetoclax in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the dose escalation and confirmation segment of the Phase 3 bellwave-010 study (ABSTRACT ID abs25-8314; ABSTRACT ID 2119) | Speaker: Paolo Ghia

A phase 2 study with tafasitamab and zanubrutinib in newly diagnosed chronic lymphocytic leukemia/small lymphocytic lymphoma – taza CLL (ABSTRACT ID abs25-14355; ABSTRACT ID 2134) | Speaker: TBC

Zanubrutinib + obinutuzumab + sonrotoclax in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL/SLL): Initial results from an ongoing phase 1/1b study, BGB-11417-101 (ABSTRACT ID abs25-4113; ABSTRACT ID 3890) | Speaker: Jacob Soumerai

Panel Discussion

Session 4: BTK degraders for CLL 

Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in Relapsed/Refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial (ABSTRACT ID abs25-4184; ABSTRACT ID 86) | Speaker: Zulfa Omer 

Updated efficacy and safety results of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the ongoing phase 1 CaDAnCe-101 study  
(ABSTRACT ID abs25-8349; ABSTRACT ID 85) | Speaker: TBC

CaDAnCe-104, an ongoing, open-label, phase 1b/2 master protocol study of Bruton tyrosine kinase degrader BGB-16673 in combination with other agents in patients with relapsed/refractory B-cell malignancies (ABSTRACT ID abs25-768; ABSTRACT ID 1839) | Speaker: Chan Cheah

Panel Discussion

Session 5: Advances with targeted therapies for CLL 

Epcoritamab combinations demonstrate promising efficacy in patients (pts) with Richter transformation (RT): First results from arms 2B (epcor + lenalidomide [LEN]) and 2C (epcor + R-CHOP) of the phase 1b/2 EPCORE CLL-1 trial (ABSTRACT ID abs25-2683; ABSTRACT ID 1015) | Speaker: TBC

Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic leukemia (ABSTRACT ID abs25-2882; ABSTRACT ID 798) | Speaker: TBC

Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton’s tyrosine kinase inhibitors (BTKis) (ABSTRACT ID abs25-13909; ABSTRACT ID 88) | Speaker: TBC

Panel Discussion

Conclusions and meeting close